Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under “fed” conditions DehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the… Read More
Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3… Read More
Victoria, BC & Vancouver, BC – StarFish Medical is pleased to announce the return of Medical Device Playbook to Vancouver, BC on October 21, 2024, from 8:45am to 6pm local time…. Read More
McCarthy Tétrault is pleased to announce that Sunil Kapur has been appointed as the firm’s next Chief Executive Officer, effective January 1, 2025. Sunil brings over a decade of senior management experience… Read More
Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms… Read More
